PainChek Ltd PCK
ASX · Australia · Technology Services
AUD 0.0960+0.00 (+1.05%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Painchek Ltd (ASX:PCK) leverages FDA clearance and a robust ARR pipeline to capitalize on significant US market opportunities, despite facing implementation challenges.
PainChek recently received FDA De Novo classification for its PainChek Adult App, making it the first regulated medical device for pain assessment in the US and enabling market access across aged care, home care, and hospitals. This regulatory clearance unlocks commercial opportunities estimated at over US$100 million annually, supported by integration partnerships covering the majority of the US and Canadian long-term care market. We'll explore how PainChek's FDA approval and immediate US...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.